We are excited to announce changes to BioReperia’s executive leadership team.
Emmelie Persson has been appointed as the new Chief Executive Officer (CEO) of BioReperia, effective immediately. Emmelie brings over 15 years of experience in the biotech industry, with a proven track record of driving growth and innovation.
“I am honored to take on the role of CEO at BioReperia,” said Emmelie Persson. “BioReperia has tremendous potential, and I look forward to working with the talented team to accelerate our mission of developing transformative biopharmaceutical solutions.”
Anna Erkstam, who previously served as CEO, will transition to the role of Chief Business Officer (CBO). In this new position, Anna will focus on strategic business development, partnerships, and expanding BioReperia’s global footprint.
“I am thrilled to take on the CBO role and dedicate my efforts towards advancing BioReperia’s business strategy,” said Anna Erkstam. “Emmelie’s leadership and vision will be invaluable as we enter this next phase of growth.”
Please join us in congratulating Emmelie and Anna on their new roles. We are confident that this leadership team will drive BioReperia’s continued success and innovation
